| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.0085 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.0076 | 0.9 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | BMS-754807 | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |